Furthermore, an extension of the approval period is required for the active substances flutolanil, mepiquat and pyraclostrobin to allow the time necessary to carry out an assessment relating to endocrine disrupting properties of those active substances in accordance with the procedure set out in Articles 13 and 14 of Implementing Regulation (EU) No 844/2012.
Recital 5, Regulation (EU) 2021/52
In forcesince 22 Jan 2021
- celex=32012R0844